drugset / Trial / NCT00409591

Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand

NCT00409591

RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to compare the efficacy of two doses of nevirapine (NVP) given only to the infants or lopinavir/ritonavir (LPV/r) from 28 weeks gestation with single dose (SD) NVP given to the mothers plus two doses to the infants, in addition to zidovudine (ZDV) prophylaxis (from 28 weeks' gestation and for one week of ZDV in neonates) for the prevention of mother-to-child transmission of HIV-1.

Timeline

Start
2008-07
Primary completion
2010-11
Completion
2015-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lopinavir Other / unclassified 400 mg
Comparator Nevirapine Small molecule 6 mg Oral
Comparator Nevirapine Small molecule 200 mg Oral
Subject Ritonavir Other / unclassified 100 mg
Background Zidovudine Small molecule